UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The Securities Exchange Act~~ of ~~1934~~the

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of ~~earliest event reported): October 19, 2015~~1934

~~TEKLA~~Date ~~WORLD~~of ~~HEALTHCARE~~report ~~FUND~~(Date of earliest event reported): December 19, 2022 (December 14, 2022)

~~(Exact~~Tekla ~~name~~World ofHealthcare ~~Registrant as specified in its charter)~~Fund

~~Massachusetts~~(Exact name of Registrant as Specified in Its Charter)

(State or other jurisdiction of incorporation)

Massachusetts	811-23037		47-3910842
(State or other jurisdiction	(Commission File Number)		(I.R.S. Employer
of incorporation)			Identification No.)

100 Federal Street, 19^th Floor
Boston, MA		02110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 772-8500

N/A

(Former name or former address, if changed since last report)

811-23037		47-3910842
(Commission File Number)		(I.R.S. Employer Identification No.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~100~~¨ ~~Federal~~Written ~~Street,~~communications ~~19th~~pursuant ~~Floor,~~to ~~Boston,~~Rule MA425 ~~02110~~under the Securities Act (17 CFR 230.425)

~~(Address~~¨ ofSoliciting ~~principal~~material ~~executive~~pursuant ~~offices,~~to ~~zip~~Rule ~~code~~14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~Registrant’s~~¨ ~~telephone~~Pre-commencement ~~number,~~communications ~~including~~pursuant ~~area~~to ~~code:~~ Rule 14d-2(~~617~~b) ~~772~~under the Exchange Act (17 CFR 240.14d-~~8500~~2(b))

~~Not~~¨ ~~Applicable~~Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (~~Former~~§230.405 ~~name~~of this chapter) or ~~former~~Rule ~~address,~~12b-2 ifof ~~changed~~the ~~since~~Securities ~~last~~Exchange Act ~~report~~of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

~~Check~~If ~~the~~an ~~appropriate~~emerging ~~box~~growth ~~below~~company, indicate by check mark if the ~~Form 8-K~~registrant has ~~filing~~elected isnot ~~intended~~ to ~~simultaneously~~use ~~satisfy~~ the ~~filing~~extended ~~obligation~~transition ofperiod ~~the~~for ~~registrant~~complying ~~under~~with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ~~following~~Exchange ~~provisions:~~Act. ¨

~~o Written~~Securities ~~communications~~registered pursuant to ~~Rule~~Section ~~425~~12(b) of ~~under~~ the ~~Securities~~ Act ~~(17 CFR 230.425)~~:

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares of Beneficial Interest, $0.01 par value		THW		New York Stock Exchange

~~o Pre-commencement~~Item ~~communications~~1.01 ~~pursuant to Rule 14d~~-~~2(b) under~~ ~~the~~Entry ~~Exchange~~into ~~Act~~a ~~(17~~Material ~~CFR~~Definitive ~~240.14d-2(b))~~Agreement

~~o Pre-commencement~~New ~~communications~~Distribution ~~pursuant~~and ~~to Rule13e~~Sub-~~4(c) under~~Placement ~~the~~Agent ~~Exchange Act (17CFR 240.13e-4(c))~~Agreements

~~Item~~Tekla 8World Healthcare Fund (NYSE: THW) (the “Fund”) has entered into a distribution agreement (the “Distribution Agreement”), dated December 14, 2022, with Foreside Fund Services, LLC (“Foreside”), pursuant to which the Fund may offer and sell common shares of beneficial interest, par value $0.01 ~~Other~~per share ~~Events~~(“Common Shares”) having an aggregate initial offering price of up to $150,000,000, from time to time, through Foreside as agent for the Fund for the offer and sale of Common Shares, in transactions deemed to be “at the market” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Offering”).

~~Tekla~~The ~~World~~Offering ~~Healthcare~~is ~~Fund~~being ~~introduces~~made ~~its~~pursuant ~~first~~to ~~fact~~a ~~card~~prospectus supplement, asdated ~~described~~December in14, 2022 and the ~~press~~accompanying ~~release~~prospectus, ~~published~~dated onDecember ~~October 19~~6, ~~2015~~2022, each of which isconstitute ~~attached~~part toof ~~this~~the ~~Current~~Fund’s effective ~~Report~~shelf registration statement on Form 8 N-K2 as(File ~~Exhibit 99~~No.1 333-267555) previously filed with the Securities and Exchange Commission (the “Registration Statement”). Under the Investment Company Act of 1940, as amended, the Fund may not sell any Common Shares at a price below the current net asset value of such Common Shares, exclusive of any distributing commission or discount.

~~Item~~Under 9the Distribution Agreement, Foreside may enter into sub-placement agent agreements with one or more selected dealers.01 ~~Financial~~Foreside ~~Statements~~has ~~and~~entered ~~Exhibits~~into a sub-placement agent agreement, dated December 14, 2022 (the “Sub-Placement Agent Agreement”), with UBS Securities LLC (“UBS”) relating to the Common Shares to be offered under the Distribution Agreement.

Exhibit No.		Description
99.1		Press release dated October 19, 2015

Pursuant to the Distribution Agreement, the Fund will compensate Foreside with respect to sales of Common Shares at a commission rate of 1.00% of the gross proceeds of the sale of Common Shares. Out of this commission, under the Sub-Placement Agent Agreement, Foreside will compensate UBS at a rate of up to 0.80% of the gross sales proceeds of the sale of the Common Shares sold by UBS.

~~SIGNATURES~~Shareholders may request free copies of the prospectus supplement, accompanying prospectus, statement of additional information, or the Fund’s annual and semi-annual reports by calling the Fund’s investment adviser, Tekla Capital Management LLC, at (617) 772-8500 or by writing the Fund c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor Boston, MA 02110, or you may obtain a copy (and other information regarding the Fund) from the SEC’s website (http://www.sec.gov).

~~Pursuant~~The toforegoing descriptions of the ~~requirements~~Distribution Agreement ofand the ~~Securities~~Sub-Placement ~~Exchange~~Agent ~~Act~~Agreement ofdo ~~1934,~~not purport to be complete and are qualified in their entirety by reference to the full ~~Registrant~~text ~~has~~of ~~duly~~the ~~caused~~Distribution Agreement filed with this report toas beExhibit ~~signed~~1.1 onand ~~its~~incorporated ~~behalf~~herein by reference, and the ~~undersigned~~full ~~hereunto~~text of ~~duly~~the ~~authorized~~Sub-Placement Agent Agreement filed with this report as Exhibit 1.2 and incorporated herein by reference.

	TEKLA WORLD HEALTHCARE FUND
Date: October 19, 2015	By:	/s/ Daniel R. Omstead
	Daniel R. Omstead
	President

Item 9.01. Financial Statements and Exhibits.

2(d) Exhibits.

1.1

Distribution Agreement between the Fund and Foreside Fund Services, LLC dated December 14, 2022

1.2

Sub-Placement Agent Agreement between Foreside Fund Services, LLC and UBS Securities LLC dated December 14, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TEKLA WORLD HEALTHCARE FUND


Date: December 19, 2022	By:	/s/ Daniel R. Omstead
		Name:	Daniel R. Omstead
		Title:	President

Filing Compare · abrdn World Healthcare Fund